Bacillus Calmette Guerin Vaccine

BIOLOGICAL2 trials

Sponsors

Massachusetts General Hospital, Fudan University

Conditions

FibromyalgiaHER-2 Protein OverexpressionNon-muscle Invasive Bladder Cancer

Phase 2

Phase II Clinical Trial: Multi-dosing the BCG Vaccine for Fibromyalgia

WithdrawnNCT03582085

Massachusetts General HospitalFibromyalgia

Start: 2026-01-01End: 2027-01-01Updated: 2024-11-21

Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer

Active, not recruitingNCT06187506

Fudan UniversityHER-2 Protein Overexpression, Non-muscle Invasive Bladder Cancer

Start: 2023-12-18End: 2027-01-01Target: 20Updated: 2026-07-20

Related Papers

Preliminary efficacy and safety of disitamab vedotin (DV) combined with bacillus Calmette-Guérin (BCG) in the treatment of high-risk non-muscle invasive bladder cancer with HER2 expression: A prospective, open label, single-center study.

Journal of Clinical Oncology2025-02-101 citations